Breast cancer is a heterogeneous disease with several subtypes that currently do not have 25 targeted therapy options. Metabolomics has the potential to uncover novel targeted treatment 26 strategies by identifying metabolic pathways required for cancer cells to survive and proliferate.
INTRODUCTION 34
Breast cancer is a heterogeneous disease with subtypes that vary by morphology, Figure 1 : Schematic overview of the experimental design for drug selection based on breast cancer subtype-specific metabolism. The epithelial mesenchymal transition (EMT) and papillary tumors are histologically distinct mouse mammary tumor subtypes from the MMTV-Myc mouse model. Cell lines derived from tumors can be used to determine metabolic pathways that can be used to select drug candidates for each subtype. are fed 13 C-glucose, the M-5 isotopologue of inosine monophosphate (IMP) and ATP can be 140 derived from either de novo or salvage pathways, while all other isotopologues of IMP and ATP
141
(M-1 to M-4 and M-6 to M-10, referred to as M-Other in Figure 4C ) can only be derived through 142 de novo biosynthetic pathways ( Figure 4A ). As shown in Figure 4C and Supplementary Table   143 1, M-Other is higher in the papillary cells for both IMP (23% in papillary vs. 19% in EMT) and ATP
144
(19% in papillary vs. 15% in EMT). Further, 13 C-glutamine labeling shows increased levels of the 145 M3 isotopologue of uridine triphosphate (UTP) in the papillary cells (23% in papillary vs. 17% in 146 EMT; Figure 4D ; Supplementary Table 2 )this isotopologue can also only be derived from de 147 novo biosynthesis ( Figure 4B) . Therefore, the papillary cells demonstrate increased de novo 148 biosynthesis of both purine and pyrimidine nucleotides compared to the EMT cells. Notably, we 149 find no difference between EMT and papillary cells in 13 C-glucose labeling into ribose-5- Figure 2 ), which indicates that increased nucleotide biosynthesis in the papillary cells is not simply due to greater abundance of labeled precursors for these pathways. Increased de novo 153 nucleotide biosynthesis could reflect a preference to utilize this metabolic pathway to generate 154 nucleotides in the papillary subtype. This would indicate targeting de novo nucleotide biosynthesis 155 is likely to be more effective in the papillary subtype. Figure 3) . 28, 29 We found that targeting each distinct metabolic feature inhibits 167 breast cancer cell proliferation in a subtype-specific manner. Since the EMT cells display 168 increased levels of both oxidized and reduced glutathione compared to papillary cells ( Figure   169 2B), they are more likely to be sensitive to glutathione biosynthesis inhibition. As expected, 170 targeting glutathione biosynthesis with BSO was more effective at inhibiting proliferation of the 171 EMT cells vs. the papillary cells (Figure 5A-B) . Consistently, the IC50 for this compound was 172 significantly lower for the EMT cells (34 µM) vs. the papillary cells (49 µM; p-value <0.0001;
Indeed, targeting TCA cycle metabolism with CPI-613 was more effective in the EMT vs. papillary vs. the papillary cells (153 µM; p-value <0.0001; Supplementary Figure 4B,D) . Finally, the 178 papillary subtype demonstrates increased de novo nucleotide biosynthesis (Figure 4) and should 179 therefore be most sensitive to compounds which target nucleotide biosynthesis. Indeed, we find 180 that targeting nucleotide metabolism with 5FU was most effective at inhibiting proliferation of the 181 papillary cells vs. the EMT cells ( Figure 5E-F) ; the IC50 for this compound was significantly lower 
